Can I Take Berberine with Wegovy? A Clinical Review

What each one does

Wegovy is available as a once-weekly semaglutide injection and as daily tablets, approved for chronic weight management alongside a reduced-calorie diet and more physical activity [2]. The usual recommended injection maintenance dose for weight reduction is 2.4 mg weekly; the label also permits up to 7.2 mg weekly in adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss [2]. It binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite, and it delays gastric emptying [2].

Berberine is a plant alkaloid from barberry, goldenseal and related plants, sold over the counter as a dietary supplement [3]. Most human trials of berberine are short (12 weeks or less), small, and done in China or Hong Kong [7]. Berberine is reported, from preclinical work, to inhibit voltage-gated potassium channels in pancreatic beta cells and promote insulin secretion only when glucose is high [1].

How much berberine actually lowers glucose

A meta-analysis of 37 randomized trials in 3,048 patients found fasting glucose down 0.82 mmol/L (95% CI -0.95 to -0.70), HbA1c down 0.63% (95% CI -0.72 to -0.53) and 2-hour glucose down 1.16 mmol/L; total adverse events and hypoglycemia were not increased [1]. The effect was larger when baseline glucose and HbA1c were higher [1].

The best-known head-to-head is a 3-month pilot in 36 adults with newly diagnosed type 2 diabetes, where berberine 500 mg three times daily lowered glucose about as much as metformin 500 mg three times daily; HbA1c fell from 9.5% to 7.5% and fasting glucose from 10.6 to 6.9 mmol/L in the berberine group [8]. A second, uncontrolled part of the same paper added berberine to 48 adults with poorly controlled diabetes and saw HbA1c fall from 8.1% to 7.3% [8]. That pilot compared berberine with metformin, rather than testing them together [8]. A review of 14 randomized trials found better glucose control when berberine was added to an oral glucose-lowering drug, but rated the methodological quality generally low [9].

Doses in the trials include 500 mg three times daily for 3 months in diabetes [8], 500 mg twice daily for 12 weeks in men with high cholesterol [6], and 900 to 1,500 mg daily for 4 to 24 weeks across 18 placebo-controlled lipid trials [5]. These are study doses, not recommended doses.

What the Wegovy label says about low blood sugar

The Wegovy label says Wegovy lowers blood glucose and can cause hypoglycemia, that the risk is higher with insulin or an insulin secretagogue, and that reducing the dose of the insulin or secretagogue should be considered when starting [2]. In a weight trial in adults with type 2 diabetes and a BMI of 27 or more, plasma glucose below 54 mg/dL occurred in 6.2% of those on Wegovy 2.4 mg versus 2.5% on placebo, and risk was higher with a sulfonylurea [2]. The label also says patients should be informed of this risk and taught the signs and symptoms of hypoglycemia [2]. Its interactions section covers insulin, insulin secretagogues and oral medicines affected by delayed gastric emptying [2].

Berberine's enzyme effects and semaglutide's clearance

Semaglutide is broken down by proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty acid side chain, not by CYP enzymes, and the label describes a very low potential to inhibit or induce CYP enzymes [2].

Berberine, by contrast, does inhibit CYP enzymes in people. In a crossover study of 17 healthy men who completed 14 days of berberine 300 mg three times daily, midazolam exposure rose about 40%, the urinary dextromethorphan/dextrorphan ratio rose about ninefold and the losartan/E-3174 ratio about doubled; there was no significant change for the omeprazole or caffeine probes [4]. The one specific drug interaction with berberine studied in patients is cyclosporine: among 52 transplant recipients taking berberine 0.2 g three times daily for 3 months, trough cyclosporine rose 88.9% versus 64.5% in 52 controls, and final levels were 29.3% higher than in the controls; a 6-patient kinetic study found cyclosporine AUC up 34.5% [10]. Those studies show berberine can affect CYP-metabolized drugs in probe studies and can raise cyclosporine levels. Effects on most other named drugs have not been studied in trials, but higher exposure is theoretically possible for sensitive CYP2D6, CYP2C9 and CYP3A4 substrates [4][10]. Semaglutide is not cleared through that route [2].

Gastric emptying and oral absorption

Wegovy delays gastric emptying, and the label advises monitoring oral medicines, particularly those with a narrow therapeutic index [2]. One related finding: a goldenseal extract standardized to berberine lowered metformin AUC by 23% (ratio 0.77, 90% CI 0.71 to 0.83) in 16 volunteers, with no change in half-life or renal clearance, while the same extract raised midazolam AUC by 43% [11]. That study used a goldenseal extract, not pure berberine.

Do the side effects overlap?

Both berberine and Wegovy can cause gastrointestinal side effects [5][2].

In the pooled Wegovy 2.4 mg trials (2,116 on Wegovy, 1,261 on placebo), nausea occurred in 44% versus 16%, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, and any gastrointestinal reaction 73% versus 47%; 6.8% versus 3.2% stopped treatment because of adverse reactions [2].

Berberine's main side effects are also gastrointestinal. In the 12 lipid trials that reported them, GI adverse events ran 2% to 23% with berberine versus 2% to 15% with placebo, with no serious adverse events [5]. In the 2008 diabetes pilot, 20 patients (34.5%) had transient GI effects, and liver and kidney function were unaffected [8]. Berberine's long-term safety is not established: the placebo-controlled lipid trials lasted 4 to 24 weeks [5], and a 2026 review reports liver, kidney, cardiovascular and immune toxicity of Berberis alkaloids under specific doses and conditions [12].

Does berberine add weight loss on top of Wegovy?

In one placebo-controlled trial of 84 men with high cholesterol (80 completed), berberine 500 mg twice daily for 12 weeks did not change BMI or waist-hip ratio compared with placebo, though total cholesterol fell 0.39 mmol/L [6]. In PCOS trials, BMI did not improve versus metformin (mean difference -0.03, 95% CI -0.46 to 0.39) [13], and a 2026 integrity reappraisal rated all four eligible PCOS trials (n=452) at high risk of compromised integrity [7]. A separate 12-week pilot reported an average weight loss of about 5 lb per subject in obese adults taking 500 mg three times daily [14]. Berberine's better-established effects are on glucose and LDL cholesterol [1][5]. For scale, semaglutide 2.4 mg produced a mean weight change of -14.9% versus -2.4% with placebo at 68 weeks in STEP 1, which enrolled 1,961 adults [15].

Pregnancy and breastfeeding

The Wegovy label says weight loss offers no benefit in pregnancy and may cause fetal harm, that Wegovy should be discontinued when pregnancy is recognized if it is being used for weight reduction, and that it should be stopped at least 2 months before a planned pregnancy because of the long half-life [2]. The label also says breastfeeding is not recommended during treatment with Wegovy tablets [2]. For berberine, safety in pregnancy is not established, and animal and laboratory data raise concern: in the laboratory it displaced bilirubin from albumin about tenfold more than phenylbutazone on a molar basis, it raised unbound bilirubin in adult rats, and the authors advised avoiding berberine-rich products in jaundiced newborns and pregnant women [16]. A 2026 toxicology review lists embryonic development among the systems affected by Berberis alkaloids under specific doses and conditions [12].

How berberine is regulated

Berberine is sold as a dietary supplement rather than a drug. Under DSHEA, manufacturers and distributors of dietary supplements are responsible for evaluating the safety and labeling of their products before marketing, and FDA can act against products that are adulterated or misbranded after they reach the market [17].